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Abstract
Background: To investigate accuracy of intraprocedural cone beam computed tomography (CBCT) compared to
fluoroscopy for detection of lipiodol retention pattern during conventional transarterial chemoembolization (cTACE)
of hepatocellular carcinoma (HCC) and its correlation with short-term response.
Methods: Between September 2013 and July 2014, 29 patients with HCC underwent chemoembolization of 51 tumors
(mean diameter 28.1 mm, range 10.0–136.3 mm). Lipiodol retention pattern was assessed by CBCT at the endpoint of
cTACE compared by fluoroscopy. Depending on the pattern of tumor covered by lipiodol three classes were defined:
complete (more than 90 %, no peripheral defects), moderate (50–90 %, some with or without peripheral defects), and
poor (less than 50 %). Tumor response was assessed by modified Response Evaluation Criteria in Solid Tumors
(mRECIST) based on follow-up contrast enhanced (CE) computed tomography (CT) or magnetic resonance
imaging (MRI) obtained 4–6 weeks post-cTACE. Correlations between lipiodol retention patterns on CBCT and
fluoroscopy as well as tumor response were assessed using multivariate logistic regression.
Results: Of 51 hepatic tumors, 40 (78.4 %) had complete response (CR); 8 (15.7 %) had partial response (PR); 1 (2.0 %)
had stable disease (SD); and 2 (3.9 %) had progressive disease (PD). The degree of lipiodol retention scored excellent,
moderate, and poor, in fluoroscopic images vs CBCT images were 23 (45.1 %) vs 39 (76.5 %), 19 (37.3 %) vs 11 (21.6 %),
and 9 (17.6 %) vs 1 (2.0 %), respectively. Lipiodol retention assessment with CBCT (Az = 0.75) is more accurate than
fluoroscopy (Az = 0.54) in predicting target tumor response. Other than lipiodol retention pattern assessed with CBCT
(p = 0.01), tumor size (p = 0.04) is an independent predictors of CR.
Conclusion: CBCT is more accurate than fluoroscopy in classification of lipiodol retention pattern in HCC tumors at the
time of cTACE. CBCT could be used as a reliable intra precedural monitoring modality of cTACE.
Keywords: Cone beam computed tomography, Fluoroscopy, Transarterial chemoembolization, Hepatocellular
carcinoma, Liver
* Correspondence: xiaodongw75@yahoo.com
1Department of Interventional Radiology, Peking University Cancer Hospital &
Institute, Key laboratory of Carcinogenesis and Translational Research
(Ministry of Education), Beijing 100142, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hu et al. Cancer Imaging  (2016) 16:32 
DOI 10.1186/s40644-016-0090-4
Background
Hepatocellular carcinoma (HCC) is the sixth most
common cancer and the third leading cause of cancer-
related-death worldwide [1]. Curative treatments includ-
ing resection, liver transplantation and local ablation are
indicated in less than 30 % of patients at the time of
diagnosis [2]. Transarterial chemoembolization (TACE)
is the current standard of care for HCC patients with
unresectable intermediate-stage disease and has been re-
ported to prolong survival [3–5].
Early assessment of the effectiveness of TACE and
identifying predictors of tumor response are crucial for
successful management. Intraprocedural image monitor-
ing is important to assess the endpoint of TACE and ap-
plication of additional treatment if needed while the
patient is still in the angiography suite.
cTACE uses iodized oil (lipiodol) (Guerbet, Aulnay-sous-
Bois, France) as a carrier of chemotherapeutic agents [6, 7]
and the degree of intratumoral lipiodol retention has been
shown to correlate with tumor necrosis and local tumor re-
currence with HCC [8, 9].
Visualizing distribution of lipiodol after chemoemboli-
zation by fluoroscopy or computed tomography (CT)
scan ensures tumor targeting [10]. However, fluoro-
scopic imaging may fail to detect lack of lipiodol accu-
mulation within the tumor [11]. Computed tomography
is more accurate to depict cross-sectional lipiodol distri-
bution [12], but it is cumbersome to transfer patients
from the angiography suite to the CT suite since the hy-
brid angiography-CT systems are not always available.
Cone beam computed tomography (CBCT) using a
flat-panel detector is increasingly used and widely avail-
able [13]. It has been shown to have lipiodol detection
rate comparable with multidetector CT imaging [14].
Lipiodol retention with the help of three dimensional
quantification software was found to correlate with
tumor response in HCC in a recently published paper
[15]. But this software is not widely available.
The goal of this study was to investigate whether gross
lipiodol retention pattern on CBCT imaging immedi-
ately after cTACE of hepatocellular carcinoma can be
used as predictor of tumor response by mRECIST, and




Authorization from the Institutional Ethics Committee
was not needed for this retrospective study in our cen-
ter. Informed consent was obtained from each patient.
All cTACE interventions performed between September
2013 and July 2014 were reviewed. From the total of 189
patients, the following were excluded: non HCC etiology
(n = 38), prior cTACE (n = 98), other treatments within
4 weeks prior to cTACE (n = 3), lack of CBCT during
cTACE (n = 12), significant image artifacts on CBCT
(n = 3), poor quality follow-up CT or MRI imaging (n = 2)
and those lost to follow-up (n = 4). The study group in-
cluded all patients (n = 29) with HCC who were eligible to
undergo their first cTACE as described below, whose
cTACE included CBCT, who had not undergone systemic
therapy within one month prior to cTACE until the first
follow-up imaging study 4–6 weeks after cTACE, who had
undergone dynamic contrast-enhanced MR or CT im-
aging within one month before cTACE and had follow up
imaging 4–6 weeks after cTACE.
The diagnosis of HCC was confirmed by biopsy or by
characteristic radiologic findings for tumors larger than
one cm in patients at risk for HCC such as cirrhotics or
hepatitis B carriers. Eligibility criteria for cTACE were as
follows: Eastern Cooperative Oncology Group (ECOG)
performance status ≤2; Child-Pugh classification A or B;
tumor involvement less than 60 % of total liver volume;
absence of portal vein tumor thrombus; absence of
ascites; albumin > 2.5 g/dl; alanine aminotransferase and
aspartate aminotransferase <5 times the upper normal
limit; total serum bilirubin <3.0 mg/dl; serum creatinine
<2.0 mg/dl; platelet count >50,000/mm3 and international
normalized ratio (INR) ≤1.5. Patient demographics and
tumor data are listed in Table 1.
Transarterial chemoembolization
All cTACE were performed using a 40 cm flat panel
angiography system (Innova 4100, GE Healthcare,
Waukesha, WI, USA). The technique for embolization
has been previously described [4, 16]. Details of the hep-
atic artery anatomy, feeding artery and location of tumors,
and portal vein patency and flow direction were obtained
from hepatic and superior mesenteric arteriography via a
5 Fr catheter. A 2.7 to 2.8 Fr microcatheter (Progreat,
Terumo, Japan) was used to selectively cannulate tumor
feeders. In cases where there were multifocal lesions in
one lobe, the micro-catheter was positioned proximally in
the feeding artery of a sector or a lobe. The emulsion con-
sisted of 5–30 ml of lipiodol (Guerbet, Aulnay-sous-Bois,
France) mixed with 40–60 ml Epirubicin (Hisun Pharma-
ceutical, Zhejiang, China), which was slowly injected
through microcatheter under fluoroscopic-monitoring.
The diameter of the index lesion in cm was multiplied by
two to calculate the volume of iodized oil in ml used to
make the emulsion. The entire emulsion was injected un-
less stasis was achieved or the portal vein around the
tumor was visualized. This was followed with injection of
particles such as 150–350 and 350–550 μm gelfoam par-
ticles (Alicon Pham SCI &TEC, Hangzhou, China) or
100–300 and 300–500 μm embosphere particles (Bio-
sphere Medical, Rockland, Massachusetts, USA) until
stasis was achieved. In cases where the territory of more
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than one vessel was treated, the emulsion was split between
the receiving vessels at the discretion of angiographer. At
the end point of cTACE based on fluoroscopy, CBCT was
performed to assess the retention pattern of lipiodol.
Cone beam computed tomography
During a 10 s acquisition, 293 projection images were ob-
tained with 180° rotation (20°/s). Cross-sectional images
with 1.8 mm slice thickness and 512 × 512 × 512 matrix
size were reconstructed from the projections. Images were
reconstructed within approximately two minutes.
Image analysis
The patterns of lipiodol retention by the tumor (s) on
CBCT and fluoroscopy images were evaluated at the
workstation (Advantage Workstation 4.3, GE Healthcare).
The retention patterns were classified by two experienced
radiologists (14, 16 years experiences in interventional
radiology) and decisions were reached by consensus. The
retention patterns were classified as “complete” (more
than 90 % dense retention of the tumor, no peripheral de-
fects), “moderate” (50–90 % dense retention, with or with-
out peripheral defects), and “poor” with less than 50 %
dense retention of the tumor, with peripheral defects or
no retention at all.
Tumor response evaluation
All study patients were evaluated by baseline CE-CT or
CE-MRI within 1 month before cTACE. The index tu-
mors were identified and baseline measurements made.
The follow-up CE-CT or CE-MRI scan was performed
4–6 weeks after cTACE. Tumor response was assessed
on the follow-up images according to the mRECIST cri-
teria [17]. Unidimensional measurement of the longest
diameter was recorded for each index tumor, which was
selected according to mRECIST standards. Tumor re-
sponses were evaluated by a third experienced radiolo-
gist (16 years experiences in abdominal imaging) who
was blinded to the study data separately.
Response was defined as follows: “complete response”
(CR) as disappearance of all intratumoral enhancement;
“partial response” (PR) as < 30 % decrease in diameters
of enhancing tumor from baseline; “progressive disease”
(PD) as > 20 % increase in diameters of enhancing
tumor from baseline; and “stable disease” (SD) as all
other tumors.
Statistical analysis
The patient demographics and tumor data were recorded
in a secure database and expressed as mean and median.
To assess risk factors for tumor response, univariate and
multivariate analyses were performed through binary lo-
gistic regression. All analyses were performed by an inde-
pendent investigator using SPSS (version 18.0). P value of
less than 0.05 was set as significant for all analyses.
Results and discussion
Lipiodol retention pattern and tumor response
The pattern of lipiodol retention was different between
fluoroscopy and CBCT (Figs. 1 and 2). In fluoroscopic
images of 51 tumors, the complete, moderate and poor
classes of lipiodol retention patterns were 23 (45.1 %),
19 (37.3 %), and 9 (17.6 %), respectively. In CBCT im-
ages, however, the results were 39 (76.5 %), 11 (21.6 %),
and 1 (2.0 %), respectively. Of all the tumors, 78.4 %
(n = 40) showed a CR, and 15.7 % (n = 8), 2.0 % (n = 1),
and 3.9 % (n = 2) showed PR, SD, and PD.
In the “excellent” retention tumors by CBCT, 34/39
tumors (87.2 %) showed CR and 5/39(12.8 %) tumors
showed PR. By comparison, in the “excellent” retention
Table 1 Baseline characteristics of patients with HCC
Characteristic No. of Patient/Mean
No. of patients 29
Age (y) 59.2 ± 11.6
Sex (male/female) 26/3
Etiology
Hepatitis B 27 (93.1 %)
Hepatitis C 1 (3.4 %)
ECOG performance status (0/1/2/3/4) 21/7/1/0/0
Status 0 21 (72.4 %)
Status 1 7 (24.1 %)
Status 2 1 (3.5 %)




< 10 5 (17.2 %)
10-400 15 (51.7 %)
> 400 9 (31.0 %)
Prior hepatic resection
Yes 7 (24.1 %)
No 22 (75.9 %)
Index tumor numbers (per patient) 3.22 ± 2.20 (1–5)
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tumors by fluoroscopy group, 18/23(78.3 %) showed CR
response, while 16/19 (84.2 %) “moderate” retention
tumors and 6/9 (66.7 %) “poor” retention tumors still
showed CR response. The pattern of lipidol retention by
CBCT versus fluoroscopy and the number of tumors
which demonstrated completed vs partial response,
stable disease, or progression of disease for CBCT versus
fluoroscopy are listed in Table 2.
Predictors of response
The accuracy for predicting tumor response by asses-
sing the accumulation of iodized oil shows significant
difference between the CBCT (Az = 0.75) and fluoros-
copy (Az = 0.54). The correlation between tumor re-
sponse was stronger with CBCT classification than
fluoroscopy classification. Thirty-four among 39 tumors
(87.2 %) in the “complete” retention tumors by CBCT
showed CR. By comparison, in the classification based on
the fluoroscopy, 18 tumors (78.3 %) out of 23 “complete”
lipiodol retention class showed CR response.
The correlation of patient, tumor, and lipiodol retention
pattern variables and CR by univariate and multivariate
analyses are reported in Tables 3 and 4. Multivariate ana-
lysis suggests that lipiodol retention pattern by CBCT and
tumor size are independent predictors of achieving a
complete radiologic response (OR 19.17, p = 0.01 and OR
0.88, p = 0.04 respectively).
Discussion
Earlier determination of the tumor response after
cTACE is essential in decision making for application
of additional treatments in patients with HCC.
Fig. 1 A 52-year-old male with multiple HCCs. a Preprocedure arterial phase contrast-enhanced CT shows index tumors in segments II and VII
(arrows); b CBCT immediately after TACE showed these two tumor with complete lipiodol retention pattern concordance with CE-CT (arrows);
c On the fluoroscopy image, complete lipiodol retention pattern is well shown on the large tumor in segment VII, but no retention in the
small tumor in segment II. d Postprocedure 1 month follow-up contrast-enhancement CT shows both tumors without contrast enhancement
(arrows) representing complete response
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Histopathologic examination for the determination of
tumor response after transarterial chemoembolization
is neither feasible nor acceptable. Imaging techniques,
such as 4–6 weeks follow-up contrast-enhanced CT
and MR imaging are widely used to evaluate the thera-
peutic effect [17, 18]. For both EASL and mRECIST cri-
teria, measurement of enhanced tumor portion rather
than the total visible tumor size has been used to
Fig. 2 A 56-year-old female with multiple HCCs and prior history of radiofrequency ablation. a, b Preprocedure arterial phase contrast-enhanced
MRI shows two tumors adjacent to the ablation margin in the right lobe (arrows); c, d Cone beam CT immediately after completion of TACE
showed these two tumors with complete lipiodol retention pattern without defect concordant with MRI; e On the fluoroscopy image, tumor
lipiodol retention was not clearly seen. f, g Postprocedure 1 month follow-up contrast-enhancement MRI showed necrosis without contrast
enhancement in both tumors (arrows) representing complete response
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evaluate tumor response in HCC patients after cTACE
[17, 19]. Based on this post-procedure assessment im-
aging, a repeat cTACE or tumor ablation would be
needed in case there was residual viable tumors were
identified.
Tumor progression for the incompletely treated tu-
mors could be expected during this time interval. Given
this risk, some investigators have reported the contrast-
enhanced ultrasonography (US) performed at least two
and seven days after cTACE could be similar to the dy-
namic follow-up CT and be predictive of tumor out-
come [20]. Some clinical studies have shown the ability
of diffusion-weighted MR imaging to help quantify
tumor necrosis after transcatheter liver-directed ther-
apy [21, 22]. However, MR or US imaging are separate
tests and require logistics for scheduling. Intraprocedural
image monitoring is important to determine the endpoint
of cTACE and application of additional treatment if
needed while in the angiography suite. Utilization of
CBCT performed at the time of cTACE for prediction of
tumor response obviates the need for additional testing.
CBCT with flat-panel detector acquired during the
cTACE procedure has been shown to have several advan-
tages such as identifying the tumor feeding arteries, occult
lesions, cyctic artery, etc. [23, 24]. Loffroy et al. showed
dual-phase CBCT can be used to predict the short term
response to TACE with drug-eluting beads [25].
cTACE with lipiodol is widely used and has compar-
able efficacy to DEB-TACE [26]. Lipiodol not only acts
as a carrier of chemotherapeutic agents, but its use has
yielded fairly beneficial therapeutic results. It exposes
the tumor to high concentrations of the chemotherapeu-
tic agents for a prolonged period of time, while minimiz-
ing systemic toxicity [27]. In this study we demonstrated
the lipiodol retention pattern on CBCT immediately
after cTACE can be used to predict the short-term
tumor response at 4–6 weeks follow-up in HCC patient
by mRECIST.
Lipiodol retention pattern after cTACE on follow-up
CT imaging has been shown to be a prognostic marker
[8, 18, 28]. Multidetector computed tomography (MDCT)
can evaluate lipiodol retention after cTACE [14], however,
the exact method for assessing lipiodol retention is to per-
form the post-procedural CT directly after cTACE and the
patient must be transferred from the angiography suite to
the CT scanner. Despite advances in the angiography unit,
fluoroscopic imaging may not accurately show lipiodol
retention pattern in the tumor because it cannot provide
volumetric information such as CBCT [11]. A combined
CT-angiography system with a stand alone CT scanner is
useful to evaluate the lipiodol retention pattern; however,
the system is expensive and requires a large room [9].
In this study, we have demonstrated that CBCT imaging
performed during cTACE is superior to fluoroscopic im-
aging for assessing the lipiodol retention pattern in HCC
tumors. A theoretical downside may be that CBCT may
be less sensitive given its inferior spatial and contrast reso-
lution compared with conventional CT [29]. However, it
offers the advantage of imaging during a cTACE proced-
ure without the necessity of transferring the patient. In
one study, Rongxin Chen et al. have reported that CBCT
imaging has a similar capability to assess Lipiodol reten-
tion as MDCT [14]. Correlation between contrast reten-
tion pattern in liver tumors detected on intraprocedural
CT images during transcatheter bland embolization and
Table 2 Lipiodol retention variables and tumor response
Variable Response
PD SD PR CR
Fluoroscopy
Excellent (23) 0 0 5 18
Moderate (19) 1 0 2 16
Poor (9) 1 1 1 6
Lip-CBCT
Excellent (39) 0 0 5 34
Moderate (11) 1 1 3 6
Poor (1) 1 0 0 0
Table 3 Univariate analysis of predictors of CR
Factors OR 95 % CI p
Patients and tumor variables
Sex (male/female) 0.73 (0.51,1.04) 0.01
Age(y) ≥ 60 vs. <60 2.07 (0.46,9.40) 0.48












Lipiodol retention on Fluoroscopy
Excellent vs. Moderate and Poor
0.76 (0.22,2.64) 0.75
Lipiodol retention on CBCT
Excellent vs. Moderate and Poor
5.17 (1.13,23.55) 0.03
Etiology
Hepatitis B virus vs. negative
2.19 (0.56,8.61) 0.27
Table 4 Multivariate models of predictors of CR
Model OR 95 % CI p
Tumor Size 0.88 (0.01,0.90) 0.04
Lipiodol retention in Lip-CBCT
Excellent vs. Moderate and Poor
19.17 (1.87,196.49) 0.01
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tumor response has been reported [30]. Strong correlation
between lipiodol retention on intraprocedural CBCT im-
aging and tumor response in HCC is shown with the help
of three dimensional quantification software [15]. Our
comparable results showing strong correlations could also
be drawn with such software.
Assessing lipiodol retention pattern by CBCT during
the cTACE procedure Provides near real-time feed-back
[14] before the patient leaves the angiography suite and
enables the operator to set a more accurate endpoint
and perform additional treatment if necessary.
This study has limitations such as small size of the
study group, its retrospective design and lack of a con-
trol group. Due to the small size of our group, interpret-
ation of CT and MRI studies obtained after cTACE and
CBCT images are prone to observer bias. The one-month
follow-up treatment response evaluation may be inferior
to the more commonly practiced 2–3 month follow-up
treatment response evaluation. This might have intro-
duced an element of bias. Our results need to be validated
further with larger and better designed studies.
Conclusion
In conclusion, during cTACE for HCC tumors cone beam
CT is more accurate in detection of lipiodol retention pat-
tern compared to fluoroscopy. The pattern of lipiodol
retention assessed by CBCT can serve as a prognostic in-
dicator of short-term response and could be a reliable
intraprocedural monitoring modility during cTACE.
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